As of March 24, 2026, RenovoRx’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer has randomized 104 of a planned 114 patients and accrued 72 of the 86 overall-survival events required for the final analysis. Enrollment remains on track to complete in the first half of 2026, positioning the study for a 2027 final readout. Two pre-specified interim analyses, triggered at the 26th event in 2023 and the 52nd event in 2025, resulted in independent recommendations to continue the trial.
The core development is twofold: TIGeR-PaC has crossed the 100-patient randomization milestone while select participating centers have begun using RenovoCath as a stand-alone, FDA-cleared drug-delivery device outside the trial context. In parallel with the pivotal program evaluating intra-arterial gemcitabine delivered via RenovoCath (IAG), the company is actively commercializing the catheter for targeted infusion across solid tumors. Early commercial activity produced approximately $900,000 in device revenue over the first nine months of 2025, with repeat orders reported and uptake extending to several high-volume, NCI-designated centers.
Strategically, this is a deliberate dual-track: sustain an event-driven, registration-intent oncology study under CDER while seeding a procedural footprint for the device within interventional oncology and IR-oncology workflows. Building device familiarity ahead of a potential IAG label decision can lower post-approval friction—training, credentialing, pharmacy coordination, and supply chains are established before the drug-device combination’s fate is known. It also provides modest revenue diversification and preserves optionality if the clinical signal proves incremental rather than transformative. The trade-off is operational tension. Off-protocol device use can test site equipoise, compete for cath lab time, and potentially complicate investigator focus, even if the stand-alone indication stays within the device’s cleared claims.
For sites, the signal is that interventional capabilities are becoming more central to oncology delivery. Adopting RenovoCath requires cross-department alignment—IR, medical oncology, anesthesia, and pharmacy—to standardize preparation of intra-arterial chemotherapy, manage procedure logistics, and ensure consistent documentation and coding. For sponsors and CROs, the accrual and event cadence suggests the TIGeR-PaC operating model has stabilized after earlier program resets common in device-enabled trials. The DMC’s continue recommendations remove near-term futility risk and help maintain PI engagement, but they do not speak to effect size. For regulators, the combination path under 21 CFR 312 with an already-cleared device underscores the increasing interplay between CDER and CDRH in drug-device oncology strategies. If positive, orphan drug designation for gemcitabine delivered via RenovoCath in pancreatic and bile duct cancers would shape market exclusivity and payer negotiations.
The next twelve months will be about execution discipline: closing the last 10 patients, sustaining monitoring quality, and managing event accrual without protocol drift. Key unknowns include the magnitude of any overall survival benefit versus standard systemic regimens, the toxicity differential achievable with localized delivery, and the handling of subsequent therapies in the statistical analysis plan. Commercially, watch whether device utilization broadens beyond trial centers, whether a distribution or co-commercialization partner emerges to scale access, and how institutions approach reimbursement for procedure-based drug delivery. The pivotal risk is straightforward: if TIGeR-PaC yields only a modest survival delta, adoption will hinge on a clear safety and quality-of-life edge and operational simplicity that offsets the need for IR infrastructure. The opportunity, if the signal is durable, is a clearer template for integrating targeted intra-arterial delivery into solid tumor care pathways—and a playbook for pairing combination-drug development with real-time device commercialization.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
